View Older Stories View More Recent Stories
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Verona Pharma shareholders approve $10 billion Merck acquisition
-
Merck enters $349M deal with Variational AI for drug discovery collaboration
-
FDA: approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection
-
Merck receives positive EU opinion for RSV prevention drug ENFLONSIA
-
Merck receives positive EU opinions for KEYTRUDA subcutaneous form and head cancer use
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Berenberg Downgrades Merck (MRK) to Hold
-
Daiichi Sankyo and Merck receive FDA breakthrough designation for ovarian cancer drug
-
Merck reports positive trial results for pneumonia vaccine in children
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Merck's oral cholesterol drug meets key goals in phase 3 trial
-
Merck to present cardiovascular disease research at ESC Congress
-
KEYTRUDA plus Padcev improves survival for bladder cancer patients
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)
-
Merck (MRK) Tops Q2 EPS by 10c; narrows forecast
-
Merck (MRK) call put ratio 1 call to 1 put into quarter results
-
Merck (MRK) August 1 weekly 157.50 straddle into quarter results
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 4% Yield
-
Merck commits to Veeva Vault CRM for commercial operations
-
Merck launches phase 3 trials for monthly HIV prevention pill
-
FDA approves Merck's BRAVECTO QUANTUM for year-long flea and tick protection
-
UBS Reiterates Buy Rating on Merck (MRK)
-
Morgan Stanley Reiterates Equalweight Rating on Merck (MRK)
-
Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)
-
FDA accepts Merck's application for HIV two-drug regimen
-
Jefferies Downgrades Verona Pharma (VRNA) to Hold
-
Merck (MRK) eyes more M&A deals from $1b–$15b, open to exceeding range - CEO
-
Stifel: 'MRK Acquisition of VRNA Should Broaden Opportunity for Ohtuvayre – A Core LGND Growth Driver'
-
Merck to acquire Verona Pharma for $10 billion to add COPD treatment
-
Certara (CERT) expands clinical technology collaboration with Merck
-
Merck to present HIV research data at IAS 2025 conference
-
UBS Reiterates Buy Rating on Merck (MRK)
-
Merck (MRK) Granted FDA Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial
-
TD Cowen on Merck (MRK): 'Enflonsia ACIP Vote Could Unlock Significant Potential'
-
Merck (MRK) Reports ACIP Recommended Use of ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Younger than 8 Months
-
Rfk Jr.'s Vaccine Panel Backs Merck's (MRK) Shot To Prevent RSV
-
Morgan Stanley Reiterates Equalweight Rating on Merck (MRK)
-
Merck (MRK) Announces Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint
-
Merck (MRK) Gains, CDC Vaccine Panel Will Review MMRV Vaccine Use In Kids Under 5
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
Merck (MRK) Announces FDA Approval of KEYTRUDA for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment
-
Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs
-
Merck (MRK) Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
-
BMO Capital: ACIP Cuts a Broad Negative To the Vaccine Space
-
Bernstein Reiterates Market Perform Rating on Merck (MRK) Following 'A Positive Event'
-
Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)
-
U.S. FDA Approves Merck’s (MRK) ENFLONSIA for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
